Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 47 | 2023 | 2132 | 4.120 |
Why?
|
| Cognitive Dysfunction | 28 | 2023 | 1095 | 2.780 |
Why?
|
| Stroke | 17 | 2023 | 315 | 2.720 |
Why?
|
| Cognition Disorders | 17 | 2015 | 1055 | 2.280 |
Why?
|
| Diet, Mediterranean | 8 | 2023 | 93 | 1.960 |
Why?
|
| Aged | 72 | 2023 | 10047 | 1.310 |
Why?
|
| Humans | 106 | 2023 | 30959 | 1.250 |
Why?
|
| Female | 72 | 2023 | 16965 | 1.190 |
Why?
|
| Brain | 18 | 2023 | 1800 | 1.150 |
Why?
|
| Dementia | 9 | 2023 | 560 | 1.140 |
Why?
|
| Cognition | 23 | 2023 | 1427 | 1.130 |
Why?
|
| Male | 68 | 2023 | 16425 | 1.110 |
Why?
|
| Biomarkers | 11 | 2023 | 733 | 1.080 |
Why?
|
| Aging | 11 | 2021 | 1727 | 1.050 |
Why?
|
| Aged, 80 and over | 39 | 2023 | 5189 | 0.980 |
Why?
|
| Chicago | 18 | 2021 | 943 | 0.950 |
Why?
|
| Stress, Psychological | 4 | 2016 | 254 | 0.930 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 21 | 0.840 |
Why?
|
| Depression | 3 | 2022 | 481 | 0.820 |
Why?
|
| Diet, Western | 1 | 2022 | 12 | 0.810 |
Why?
|
| Attitude | 1 | 2022 | 32 | 0.810 |
Why?
|
| Cardiology | 1 | 2022 | 75 | 0.760 |
Why?
|
| Amyloid beta-Peptides | 7 | 2023 | 328 | 0.750 |
Why?
|
| Community Participation | 1 | 2020 | 16 | 0.720 |
Why?
|
| Prospective Studies | 11 | 2023 | 1897 | 0.660 |
Why?
|
| Neuropsychological Tests | 13 | 2021 | 1316 | 0.660 |
Why?
|
| Longitudinal Studies | 21 | 2021 | 1505 | 0.640 |
Why?
|
| Hypertension | 6 | 2022 | 288 | 0.620 |
Why?
|
| tau Proteins | 6 | 2023 | 229 | 0.620 |
Why?
|
| Brain Concussion | 3 | 2023 | 13 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 1311 | 0.620 |
Why?
|
| Apolipoproteins E | 10 | 2023 | 270 | 0.610 |
Why?
|
| Football | 3 | 2023 | 37 | 0.610 |
Why?
|
| Disease Progression | 8 | 2023 | 830 | 0.600 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2013 | 40 | 0.570 |
Why?
|
| Risk Factors | 23 | 2023 | 2586 | 0.560 |
Why?
|
| Sex Characteristics | 4 | 2023 | 144 | 0.560 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 148 | 0.560 |
Why?
|
| Apolipoprotein E4 | 9 | 2021 | 258 | 0.550 |
Why?
|
| Independent Living | 5 | 2023 | 321 | 0.540 |
Why?
|
| Cohort Studies | 16 | 2023 | 2042 | 0.510 |
Why?
|
| Cerebral Infarction | 2 | 2013 | 164 | 0.460 |
Why?
|
| Incidence | 12 | 2023 | 785 | 0.460 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 428 | 0.450 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 1009 | 0.430 |
Why?
|
| Dietary Approaches To Stop Hypertension | 3 | 2021 | 31 | 0.410 |
Why?
|
| Middle Aged | 18 | 2023 | 10192 | 0.400 |
Why?
|
| Dietary Supplements | 5 | 2022 | 63 | 0.390 |
Why?
|
| Brain Infarction | 2 | 2023 | 74 | 0.390 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 10 | 0.380 |
Why?
|
| Diet Surveys | 3 | 2022 | 23 | 0.380 |
Why?
|
| Sex Factors | 6 | 2023 | 510 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 39 | 0.370 |
Why?
|
| Smoking | 3 | 2012 | 197 | 0.350 |
Why?
|
| Neuroimaging | 4 | 2021 | 144 | 0.340 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 119 | 0.340 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 98 | 0.340 |
Why?
|
| White Matter | 3 | 2022 | 157 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 450 | 0.320 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 314 | 0.300 |
Why?
|
| Healthy Lifestyle | 3 | 2022 | 38 | 0.280 |
Why?
|
| Population Surveillance | 2 | 2021 | 123 | 0.280 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 32 | 0.280 |
Why?
|
| Women's Health | 2 | 2019 | 242 | 0.280 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 207 | 0.280 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 44 | 0.280 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.280 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 7 | 0.280 |
Why?
|
| Folic Acid | 1 | 2006 | 16 | 0.270 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 1210 | 0.270 |
Why?
|
| Urban Health | 1 | 2006 | 24 | 0.260 |
Why?
|
| Patient Selection | 2 | 2021 | 246 | 0.260 |
Why?
|
| Time Factors | 5 | 2021 | 1672 | 0.260 |
Why?
|
| Diet | 5 | 2022 | 194 | 0.260 |
Why?
|
| Comorbidity | 5 | 2021 | 508 | 0.260 |
Why?
|
| Movement Disorders | 1 | 2006 | 118 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 309 | 0.250 |
Why?
|
| Vitamin D | 2 | 2022 | 42 | 0.250 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 368 | 0.230 |
Why?
|
| Overweight | 2 | 2022 | 69 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2022 | 716 | 0.230 |
Why?
|
| Parkinson Disease | 4 | 2022 | 1069 | 0.230 |
Why?
|
| Early Diagnosis | 2 | 2020 | 69 | 0.220 |
Why?
|
| Risk | 5 | 2015 | 220 | 0.220 |
Why?
|
| Day Care, Medical | 3 | 2008 | 5 | 0.220 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 36 | 0.210 |
Why?
|
| Gender Identity | 2 | 2023 | 24 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 1922 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 191 | 0.210 |
Why?
|
| Life Style | 5 | 2023 | 226 | 0.210 |
Why?
|
| Exercise | 3 | 2022 | 507 | 0.200 |
Why?
|
| Crime Victims | 1 | 2022 | 25 | 0.200 |
Why?
|
| United States | 8 | 2022 | 2373 | 0.200 |
Why?
|
| Food | 1 | 2022 | 32 | 0.200 |
Why?
|
| Health Status Disparities | 2 | 2019 | 74 | 0.200 |
Why?
|
| Genetic Testing | 1 | 2022 | 63 | 0.200 |
Why?
|
| Genetic Loci | 3 | 2020 | 65 | 0.200 |
Why?
|
| Lutein | 1 | 2021 | 5 | 0.200 |
Why?
|
| Zeaxanthins | 1 | 2021 | 5 | 0.200 |
Why?
|
| Carotenoids | 1 | 2021 | 13 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 86 | 0.190 |
Why?
|
| Causality | 3 | 2011 | 54 | 0.190 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 12 | 0.180 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 7 | 0.180 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 31 | 0.180 |
Why?
|
| Program Development | 1 | 2020 | 73 | 0.180 |
Why?
|
| Endothelium | 1 | 2020 | 14 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2021 | 184 | 0.180 |
Why?
|
| Advance Care Planning | 1 | 2020 | 17 | 0.170 |
Why?
|
| Terminal Care | 1 | 2020 | 32 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2020 | 52 | 0.170 |
Why?
|
| Genotype | 4 | 2016 | 419 | 0.170 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 16 | 0.160 |
Why?
|
| Women's Health Services | 1 | 2018 | 12 | 0.160 |
Why?
|
| Parkinsonian Disorders | 1 | 2022 | 234 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2018 | 20 | 0.160 |
Why?
|
| Multiple Sclerosis | 2 | 2010 | 84 | 0.160 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 32 | 0.160 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 11 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 30 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 30 | 0.150 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 20 | 0.150 |
Why?
|
| Mortality | 2 | 2016 | 89 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 43 | 0.150 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2017 | 1 | 0.150 |
Why?
|
| Amyloid | 3 | 2022 | 58 | 0.150 |
Why?
|
| Public Health | 1 | 2018 | 68 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 63 | 0.140 |
Why?
|
| Self Report | 2 | 2022 | 231 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2018 | 76 | 0.140 |
Why?
|
| Prevalence | 4 | 2021 | 500 | 0.140 |
Why?
|
| Homes for the Aged | 2 | 2007 | 9 | 0.140 |
Why?
|
| Cognitive Aging | 1 | 2018 | 87 | 0.140 |
Why?
|
| Linear Models | 2 | 2015 | 273 | 0.140 |
Why?
|
| Nursing Homes | 2 | 2007 | 36 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.130 |
Why?
|
| Adult | 9 | 2023 | 8924 | 0.130 |
Why?
|
| Communication | 1 | 2017 | 120 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 164 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2016 | 23 | 0.130 |
Why?
|
| Age Factors | 4 | 2019 | 872 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2015 | 50 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 36 | 0.130 |
Why?
|
| Clergy | 2 | 2006 | 90 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2015 | 31 | 0.120 |
Why?
|
| Logistic Models | 3 | 2011 | 409 | 0.120 |
Why?
|
| Age Distribution | 2 | 2011 | 96 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 132 | 0.120 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 111 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2015 | 320 | 0.120 |
Why?
|
| Tissue Donors | 2 | 2012 | 81 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2011 | 291 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 158 | 0.110 |
Why?
|
| Antioxidants | 2 | 2005 | 65 | 0.110 |
Why?
|
| Heart Failure | 3 | 2022 | 219 | 0.110 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 22 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 356 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2012 | 28 | 0.100 |
Why?
|
| Residence Characteristics | 2 | 2011 | 226 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 36 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 549 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2011 | 89 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 919 | 0.100 |
Why?
|
| Social Support | 1 | 2012 | 194 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2022 | 261 | 0.090 |
Why?
|
| Alleles | 3 | 2021 | 227 | 0.090 |
Why?
|
| Neocortex | 1 | 2010 | 34 | 0.090 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2010 | 5 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2023 | 118 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2010 | 70 | 0.090 |
Why?
|
| Interleukin-7 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 2 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 7 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 17 | 0.080 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 104 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 150 | 0.080 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 138 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 101 | 0.080 |
Why?
|
| Psychometrics | 1 | 2010 | 270 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2010 | 190 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2021 | 3658 | 0.080 |
Why?
|
| Community Health Services | 1 | 2009 | 31 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2005 | 96 | 0.080 |
Why?
|
| Community Health Nursing | 1 | 2008 | 12 | 0.080 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 238 | 0.080 |
Why?
|
| Home Care Services | 1 | 2008 | 21 | 0.070 |
Why?
|
| Vitamin E | 2 | 2005 | 29 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2010 | 498 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2022 | 22 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 15 | 0.070 |
Why?
|
| Education | 1 | 2006 | 41 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 99 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 52 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 697 | 0.070 |
Why?
|
| Patient Admission | 1 | 2005 | 30 | 0.060 |
Why?
|
| Research Design | 2 | 2021 | 219 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2015 | 660 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 407 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 7 | 0.060 |
Why?
|
| Memory | 2 | 2006 | 328 | 0.060 |
Why?
|
| Seafood | 1 | 2003 | 10 | 0.060 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 11 | 0.060 |
Why?
|
| Caloric Restriction | 1 | 2023 | 16 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2019 | 177 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2003 | 22 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 213 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 7 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 341 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 20 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 24 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 9 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 103 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 10 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 26 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 61 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2022 | 67 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 41 | 0.050 |
Why?
|
| Vegetables | 1 | 2021 | 20 | 0.050 |
Why?
|
| Frailty | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 148 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 98 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 79 | 0.050 |
Why?
|
| Atrial Appendage | 1 | 2022 | 57 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 66 | 0.050 |
Why?
|
| Athletes | 1 | 2021 | 78 | 0.050 |
Why?
|
| Accelerometry | 1 | 2021 | 94 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 7 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 107 | 0.050 |
Why?
|
| Weight Loss | 1 | 2022 | 117 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2022 | 108 | 0.050 |
Why?
|
| Neurofibrillary Tangles | 1 | 2022 | 199 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2020 | 25 | 0.050 |
Why?
|
| Executive Function | 1 | 2021 | 125 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2020 | 32 | 0.050 |
Why?
|
| Tremor | 1 | 2022 | 141 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2022 | 114 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2022 | 97 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 267 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 148 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 85 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 2060 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 16 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 351 | 0.040 |
Why?
|
| Nutrition Assessment | 3 | 2005 | 34 | 0.040 |
Why?
|
| Survival Rate | 2 | 2011 | 404 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 3806 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 194 | 0.040 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 24 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 243 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 2 | 0.040 |
Why?
|
| Indian Ocean Islands | 1 | 2018 | 2 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 280 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 328 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 336 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 20 | 0.040 |
Why?
|
| Caregivers | 1 | 2020 | 156 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 87 | 0.040 |
Why?
|
| Ambulances | 1 | 2017 | 1 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 4722 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2012 | 134 | 0.040 |
Why?
|
| Pregnancy | 1 | 2018 | 404 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 216 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 11 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 221 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 239 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 203 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2018 | 156 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 47 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 33 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 26 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 377 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 7 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 176 | 0.030 |
Why?
|
| Educational Status | 2 | 2007 | 312 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 42 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2015 | 206 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 1133 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 127 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 353 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 29 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 782 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 5 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2010 | 7 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 31 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 64 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2010 | 46 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2010 | 110 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 58 | 0.020 |
Why?
|
| Nursing Administration Research | 1 | 2008 | 5 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 49 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2008 | 44 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 68 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 335 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2006 | 13 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2006 | 52 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2007 | 132 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2005 | 21 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 41 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2005 | 120 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 135 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 8 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 11 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 344 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 2399 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 8 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 7 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 8 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2003 | 18 | 0.010 |
Why?
|
| beta Carotene | 1 | 2002 | 7 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 53 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 35 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 148 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 134 | 0.010 |
Why?
|